Rivaroxaban vs. Vitamin K Antagonists for Antiphospholipid Antibody Syndrome

Rivaroxaban failed to demonstrate noninferiority to VKAs in preventing recurrent thrombosis.

Vitamin K antagonists (VKAs) such as warfarin have been the mainstay of therapy for patients with antiphospholipid antibody syndrome (APS). Recent trials have evaluated APS therapy with direct oral anticoagulants (DOACs), given their predictability and reliability. But concerns have been raised about the efficacy of DOACs in this setting.

Noting limitations in the prior trials, such as early study termination and the use of a laboratory surrogate as an outcome, investigators have conducted a 3-year randomized, open-label, noninferiority trial comparing the efficacy and safety of the DOAC rivaroxaban with that of VKAs in preventing recurrent thrombosis in 190 adults with thrombotic APS. The majority of patients were women with primary APS and…

Reviewing Author

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Brady L. Stein, MD, MHS

Disclosures

Leadership Positions in Professional SocietiesAmerican Society of Hematology (Senior Editor, ASH Self-Assessment Program; guideline development)

Rivaroxaban vs. Vitamin K Antagonists for Antiphospholipid Antibody Syndrome

Topics

Reviewing Author